… trial, presented at San Antonio Breast Cancer Symposium, and what questions and … giredestrant in breast cancer. The phase 3 lidERA trial compared giredestrant (Genentech, Roche … endocrine therapy for early-stage breast cancer.” Sources/Disclosures Healio …

… outcomes in HER2-positive metastatic breast cancer. Results of the trial, … Herceptin, Genentech) and pertuzumab (Perjeta, Genentech), were presented at San Antonio Breast Cancer Symposium … any patient with HER2-positive breast cancer, but particularly in that …

… with advanced HER2-positive breast cancer confirmed through an FDA … s Perjeta, developed by Genentech, was first approved in … untreated HER2-positive metastatic breast cancer. The FDA also cleared … with advanced HER2-positive breast cancer who had not …

… IDFS excluding second primary non-breast cancer. Secondary end points included … Pharma/AstraZeneca, Eli Lilly, Genentech Inc., Gilead, Menarini, Merck, … III lidERA Breast Cancer trial. Presented at: 2025 San Antonio Breast Cancer Symposium; December …

… treatment for HER2-positive breast cancer patients. The new … s Perjeta, developed by Genentech, was first approved in … untreated HER2-positive metastatic breast cancer. The FDA also cleared … patients with HER2-positive breast cancer eligible for treatment with …

… and pertuzumab delayed metastatic breast cancer progression. Tucatinib almost doubled … maintenance therapy delayed metastatic breast cancer progression for HER2-positive … (Perjeta, Genentech). Results were presented at San Antonio Breast Cancer Symposium. …

… reshaping treatment paradigms across breast cancer subtypes. This year’s … foundational in HR+ metastatic breast cancer and provide clinicians with confidence … (Perjeta; Genentech) following induction therapy in metastatic HER2+ breast cancer. Results showed …

… ;Optimizing Cardiac Outcomes in Breast Cancer—The Next Chapter." … auto-generated. Transcript Which breast cancer therapies pose the greatest … maintenance or for advanced breast cancer, which are not … as bevacizumab or Avastin (Genentech), have also been …

… with HER2+ breast cancers across various disease … Genentech, Inc) in this setting for patients with HER2+ early breast cancer … breast cancer. In heavily pretreated patients with early breast cancer … residual invasive breast cancer following neoadjuvant therapy …

… positive, HER2-negative metastatic breast cancer, particularly those who received … all patients with metastatic breast cancer.” Accordingly, Rugo and … Roche/AG/Genentech,Lilly, Merck, Novartis, … Roche/AG/Genentech, and Stemline Therapeutics. …